The PSA value at the screening visit should be ≥2μg/L (2 ng/mL). (2).Soft tissue disease progression defined by RECIST v1.1. Participants whose disease spread is limited to regional pelvic lymph nodes will be considered eligible. (3).Bone disease progression with 2 or more new lesions on bone scan. *Participants who received an anti-androgen must have progression after withdrawal ( ≥4 weeks since last flutamide administration or ≥6 weeks since last bicalutamide or nilutamide administration) x) Participants with bone-only disease may not be eligible if a soft tissue fresh pre- treatment and on-treatment tumor biopsies cannot be provided. xi)“Not applicable as per revised protocol 03 ” Participants must have received 1 but not more than 2 prior regimens for castration-resistant disease. If docetaxel chemotherapy is used more than once, this will be considered as one regimen. xii) Participants must have received 1 but not more than 3 prior regimens for castration- resistant disease. If docetaxel chemotherapy is used more than once, this will be considered as one regimen. xiii) Participants must have been offered and/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists. Reason(s) for refusal should be documented. e) UCC i) Participants must have histological or cytological evidence of metastatic or surgically unresectable transitional cell carcinoma of the urothelium involving the bladder, urethra, ureter, or renal pelvis. Minor hi stologic variants (< 50% overall) are acceptable. ii) Participants must have metastatic or surgically unre sectable disease. iii) Participants must have progression or recurrence after treatment: (1).“Not applicable as per revised protocol 03” With at least 1 platinum-containing chemotherapy regimen (if platinum eligible) but no more than 2 for metastatic or surgically unresectable locally advanced urothelial cancer, or (2).Within 12 months of peri-operative (neo-adjuvant or adjuvant) treatment with a platinum agent in the setting of cys tectomy for localized mu scle-invasive urothelial cancer. (3).With at least 1 platinum-containing chemotherapy regimen (if platinum eligible) but no more than 3 for metastatic or surgically unresectable locally advanced urothelial cancer. Revised Protocol No.: 04 Date: 31-May-2019 74 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS iv) Sequential chemotherapy given as a pl anned sequence to optimize response will count as 1 regimen. v) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists.